1. Growth hormone benefits children with 18q deletions
- Author
-
Robin J. Leach, Margaret Semrud-Clikeman, Celia I. Kaye, John E. Cornell, Lynda T. Wells, L. Jean Hardies, Nora M. Thompson, Jack L. Lancaster, Patricia D. Ghidoni, Rebecca L. Schaub, Tanzy Love, Daniel E. Hale, Peter T. Fox, and Jannine D. Cody
- Subjects
medicine.medical_specialty ,Time Factors ,Developmental Disabilities ,Intelligence ,Growth hormone ,Growth hormone deficiency ,Internal medicine ,Cognitive Changes ,Genetics ,medicine ,Humans ,Abnormalities, Multiple ,skin and connective tissue diseases ,Child ,Genetics (clinical) ,Growth Disorders ,Treated group ,medicine.diagnostic_test ,Intelligence quotient ,business.industry ,Human Growth Hormone ,Brain ,Magnetic resonance imaging ,medicine.disease ,Magnetic Resonance Imaging ,Body Height ,Growth hormone treatment ,Endocrinology ,Treatment Outcome ,El Niño ,Child, Preschool ,sense organs ,Chromosome Deletion ,business ,Chromosomes, Human, Pair 18 - Abstract
Most individuals with constitutional deletions of chromosome 18q have developmental delays, dysmyelination of the brain, and growth failure due to growth hormone deficiency. We monitored the effects of growth hormone treatment by evaluating 23 individuals for changes in growth, nonverbal intelligence quotient (nIQ), and quantitative brain MRI changes. Over an average of 37 months, the treated group of 13 children had an average nIQ increase of 17 points, an increase in height standard deviation score of 1.7, and significant change in T1 relaxation times in the caudate and frontal white matter. Cognitive changes of this magnitude are clinically significant and are anticipated to have an effect on the long-term outcomes for the treated individuals.
- Published
- 2005